Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro and in vivo studies showed the peptides’ ability to induce bone formation by stimulating osteoblast differentiation and inhibiting osteoclast differentiation.

This new and unique mechanism of action supports the development of a new therapeutic approach for the treatment of osteoporosis and several rare diseases that are associated with impaired bone metabolism.

Alizé Pharma III SAS is a new company, created for this project. It was set up to select a drug candidate based on a lead optimization program and advance it to the clinical stage.

The inventors of the IGFBP-2- based technology are Dr. David Clemmons, chief of the division of endocrinology and metabolism, School of Medicine, University of North Carolina at Chapel Hill and Dr. Clifford Rosen, the director of clinical and translational research, and a senior staff scientist at Maine Medical Center’s Research Institute, Portland, Maine.

The University of North Carolina and the University of Maine own the patent on the IGFBP-2 peptides. The patent was originally licensed to New Paradigm Therapeutics Inc. (NPT Inc.), a University of North Carolina spin-off company founded by Dr. Clemmons.

NPT Inc. has granted an exclusive sublicense to Alizé Pharma III SAS. Both companies will now collaborate on the development of a new therapy targeting bone diseases. According to the terms of the agreement, Alizé Pharma III SAS will pay NPT Inc. an agreed percentage of its licensing or divestment revenues.

Dr. David Clemmons, CEO of NPT Inc. and a key opinion leader in endocrinology and metabolism, said:

I am very pleased to enter this collaboration with Alizé Pharma, a logical partner for us, based on its know-how and track record in the development of therapeutic peptides for metabolic disorders. I look forward to moving our studies into the drug optimization and development phases in order to provide patients with a much needed anabolic bone therapy in the near future.

“We are delighted to cement a partnership with Dr Clemmons and NPT on this program targeting important unmet medical needs. According to our business model, Alizé Pharma III SAS will develop a product up to the clinical stage and then license or divest the program to a pharma partner,” said Thierry Abribat, manager of TAB Consulting, founder of Alizé Pharma III SAS. “I am pleased to announce that the first financing round is currently in progress. We are also open to any further enquiries.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Europe's new clinical guidelines enable better understanding of childhood bone cancer